sever
acut
respiratori
syndrom
sar
caus
infect
sarsassoci
coronaviru
sarscov
character
sever
pulmonari
inflamm
fibrosi
studi
develop
autoantibodi
human
epitheli
cell
endotheli
cell
patient
sar
differ
time
period
first
week
phase
month
diseas
onset
phase
iiphas
iii
investig
antibodi
sera
patient
healthi
control
human
pulmonari
epitheli
celllin
human
umbil
venou
endotheli
cell
huvec
primari
human
pulmonari
endotheli
cell
hpec
detect
cellbas
elisa
indirect
immunofluoresc
stain
result
reveal
serum
level
igg
cell
antibodi
igg
antihuvec
antibodi
igm
antihpec
antibodi
significantli
higher
sar
patient
phase
iiphas
iii
healthi
control
sera
sar
patient
phase
ii
phase
iii
could
mediat
complement
depend
cytotox
cell
hpec
conclud
autoantibodi
human
epitheli
cell
endotheli
cell
would
develop
sarscov
infect
phenomenon
may
indic
postinfecti
cellular
injuri
also
induc
sarsinduc
immunopatholog
sever
acut
respiratori
syndrom
sar
caus
infect
sarsassoci
coronaviru
sarscov
character
sever
pulmonari
inflamm
fibrosi
studi
develop
autoantibodi
human
epitheli
cell
endotheli
cell
patient
sar
differ
time
period
first
week
phase
month
diseas
onset
phase
iiphas
iii
investig
antibodi
sera
patient
healthi
control
human
pulmonari
epitheli
celllin
human
umbil
venou
endotheli
cell
huvec
primari
human
pulmonari
endotheli
cell
hpec
detect
cellbas
elisa
indirect
immunofluoresc
stain
result
reveal
serum
level
igg
cell
antibodi
igg
antihuvec
antibodi
igm
antihpec
antibodi
significantli
higher
sar
patient
phase
iiphas
iii
healthi
control
sera
sar
patient
phase
ii
phase
iii
could
mediat
complement
depend
cytotox
cell
hpec
conclud
autoantibodi
human
epitheli
cell
endotheli
cell
would
develop
sarscov
infect
phenomenon
may
indic
postinfecti
cellular
injuri
also
induc
sarsinduc
immunopatholog
j
med
virol
earli
new
infecti
diseas
sever
acut
respiratori
syndrom
sar
swept
world
includ
taiwan
twu
et
al
pathogen
later
identifi
sarsassoci
coronaviru
sarscov
spread
close
contact
droplet
drosten
et
al
yeh
et
al
infect
viru
present
persist
high
fever
cough
dyspnea
diseas
may
eventu
progress
respiratori
andor
multipl
organ
failur
fowler
et
al
tsang
et
al
autopsi
patient
die
sar
reveal
extens
pulmonari
consolid
local
hemorrhag
necrosi
prolifer
desquam
alveolar
epitheli
cell
monocyt
lymphocyt
plasma
cell
infiltr
alveoli
hyalin
membran
format
ding
et
al
frank
et
al
system
vascul
also
found
character
edema
thrombosi
local
fibrinoid
necrosi
infiltr
monocyt
lymphocyt
plasma
cell
vessel
wall
mani
organ
includ
heart
lung
liver
kidney
stroma
striat
muscl
ding
et
al
patholog
chang
thought
mediat
direct
viral
destruct
follow
immunemedi
process
peiri
et
al
epitheli
cell
endotheli
cell
accord
patholog
find
may
two
major
target
cell
damag
inflammatori
process
sar
autoantibodi
epitheli
cell
detect
recurr
oral
ulcer
ulcer
coliti
prostat
cancer
ablin
snook
et
al
sun
et
al
antiendotheli
cell
antibodi
aeca
also
found
mani
disord
system
lupu
eyrthematosu
sle
kawasaki
diseas
purpura
hsp
behcet
diseas
postinfecti
immunemedi
diseas
carvalho
et
al
toyoda
et
al
grunebaum
et
al
yang
et
al
lee
et
al
lin
et
al
although
condit
appear
result
inflammatori
tissu
injuri
other
pathogen
potenti
induc
damag
aim
studi
investig
develop
autoantiboi
human
epitheli
cell
endotheli
cell
sarscoronaviru
infect
use
cellbas
elisa
indirect
immunofluoresc
stain
identifi
pathogen
role
antibodi
twentytwo
previous
healthi
chines
adult
suffer
sar
earli
includ
studi
diagnosi
confirm
typic
clinic
present
fever
cough
dyspnea
posit
viral
pcr
inform
consent
institut
approv
obtain
studi
blood
sampl
first
oneweek
phase
month
diseas
onset
phase
ii
phase
iii
peiri
et
al
twenti
healthi
adult
enrol
control
studi
indirect
immunofluoresc
stain
patient
streptococc
necrot
pneumonia
also
recruit
control
safeti
serum
sampl
deriv
patient
inactiv
min
test
detect
presenc
antisarscov
nucleocapsid
n
antibodi
sar
patient
micropl
coat
purifi
hisn
protein
concentr
mgml
well
block
phosphat
buffer
salin
pb
contain
pb
tween
sigma
bovin
serum
albumin
bsa
hr
dilut
serum
sampl
sar
patient
phase
iiphas
iii
healthi
control
bsa
ad
well
room
temperatur
hr
remov
follow
wash
procedur
peroxidaseconjug
mous
antihuman
igg
iga
igm
bsa
ad
well
incub
room
temperatur
hr
plate
wash
pb
tween
ad
teramethylbezidin
tmb
kpl
usa
substrat
reaction
stop
addit
n
h
optic
densiti
od
well
read
wavelength
nm
minu
nm
elisa
reader
serum
level
antibodi
patient
control
express
od
valu
cell
human
pulmonari
epitheli
celllin
cultur
dmem
supplement
heatinactiv
fetal
calf
serum
fc
mm
lglutamin
mm
hepe
mgml
penicillin
streptomycin
primari
human
pulmonari
endotheli
cell
hpec
cultur
mv
singlequot
usa
supplement
ebm
cambrex
bio
scienc
walkersvil
inc
usa
human
umbil
venou
endotheli
cell
huvec
obtain
human
umbil
vein
collagenas
gibco
brl
life
technolog
digest
describ
previous
jaff
et
al
separ
cell
seed
ml
flask
precoat
gelatin
solut
grown
medium
gibco
brl
life
technolog
supplement
heat
inactiv
fc
heparin
sulfat
lglutamin
endotheli
cell
growth
factor
bm
final
concentr
mgml
mgml
penicillin
streptomycin
cultur
incub
co
cell
use
passag
cellbas
elisa
huvec
hpec
prepar
detect
autoantibodi
sera
sar
patient
cell
seed
gelatinco
microtitr
plate
nunc
tm
denmark
concentr
cell
well
cellular
growth
becam
confluent
day
later
cell
fix
glutaraldehyd
pb
min
room
temperatur
incub
block
buffer
tri
ddh
min
prevent
nonspecif
bind
wash
pbstween
serum
sampl
dilut
block
buffer
iggigm
detect
iga
detect
incub
h
sera
remov
plate
wash
ml
peroxidaseconjug
rabbit
antihuman
igg
igm
iga
immunoglobulin
ad
well
h
wash
tmb
solut
ad
min
stop
solut
hydrochlor
acid
min
od
well
read
nm
elisa
reader
initi
screen
sle
hsp
patient
immunofluoresc
stain
elisa
identifi
patient
high
antibodi
bind
activ
three
cell
type
adopt
posit
control
sle
serum
igg
igm
detect
hsp
serum
iga
detect
normal
control
serum
rel
low
bind
activ
use
neg
control
result
express
elisa
ratio
er
absorb
sampl
absorb
neg
control
b
posit
control
indirect
immunofluoresc
stain
hpec
huvec
prepar
teflonprint
slide
fix
paraformaldehyd
overnight
incub
block
buffer
fetal
calf
serum
pb
min
cell
slide
incub
sera
sar
patient
patient
necrot
pneumonia
healthi
control
hr
slide
wash
three
time
pb
fitcconjug
antihuman
immunoglobulin
chemicon
australia
dilut
block
buffer
ad
well
hr
interact
cell
pb
without
ad
serum
neg
control
establish
background
variou
immunofluoresc
stain
specimen
wash
three
time
mount
glycerol
examin
use
fluoresc
microscop
cell
seed
cultur
plate
cellswel
overnight
cell
lysi
assay
cultur
medium
replac
test
medium
supplement
mm
lglutamin
without
phenol
red
addit
patient
sera
patient
normal
control
sera
preheat
min
inactiv
complement
dilut
dilut
incub
lowtoxm
rabbit
complement
dilut
celardan
laboratori
ltd
hornbi
ontario
canada
min
ad
cell
incub
hr
level
lactat
dehydrogenas
activ
cultur
supernat
determin
use
cytotox
detect
kit
boehring
mannheim
gmbh
germani
absorb
sampl
measur
nm
refer
wavelength
nm
determin
cytotox
index
absorb
valu
substitut
follow
equat
cytotox
index
sampl
control
high
control
low
control
absorb
supernat
cell
cultur
test
medium
high
control
absorb
supernat
cell
cultur
triton
test
medium
valu
od
elisa
ratio
cytotox
index
express
mean
ae
sem
twogroup
comparison
conduct
use
mannwhitney
u
test
twotail
p
valu
less
consid
statist
signific
serum
level
antibodi
sarscov
nucleocapsid
protein
sar
patient
phase
iiphas
iii
healthi
control
examin
compar
result
show
igg
igm
antin
protein
antibodi
elev
significantli
sar
patient
igg
ae
vs
ae
p
igm
ae
vs
ae
p
statist
differ
iga
isotyp
sar
patient
healthi
control
ae
vs
ae
p
fig
antiendotheli
cell
antibodi
aeca
detect
cellbas
elisa
figur
summar
elisa
ratio
serum
antibodi
igg
iga
igm
cell
hpec
huvec
healthi
control
sar
patient
differ
time
period
phase
phase
iiphas
iii
first
week
phase
patient
present
high
fever
gener
malais
myalgia
cough
level
antibodi
period
differ
patient
healthi
control
diseas
progress
patient
receiv
combin
therapi
ribavirin
intraven
immunoglobulin
steroid
although
serum
sampl
period
collect
treatment
serum
level
igg
cell
antibodi
igm
antihpec
antibodi
igg
antihuvec
antibodi
significantli
increas
compar
healthi
control
igg
cell
ae
vs
ae
p
igm
antihpec
antibodi
ae
vs
ae
p
igg
antihuvec
antibodi
ae
vs
ae
p
level
iga
antihpec
antibodi
iga
antihuvec
antibodi
patient
matter
phase
phase
iiphas
iii
differ
statist
healthi
control
howev
two
antibodi
decreas
significantli
acut
phase
comparison
differ
phase
iga
antihpec
antibodi
ae
vs
ae
p
iga
antihuvec
antibodi
ae
vs
ae
p
fig
c
studi
autoantibodi
cell
figur
b
c
show
igg
cell
igm
antihpec
igg
antihuvec
antibodi
exist
sar
patient
phase
iiphas
iii
healthi
control
patient
necrot
pneumonia
also
sever
pulmonari
inflamm
damag
present
experi
purifi
igg
igm
immunoglobulin
avail
due
limit
regard
blood
sampl
sar
patient
therefor
order
investig
autoantibodi
pathogen
effect
sera
sar
patient
highlevel
autoantibodi
use
cytotox
assay
result
show
presenc
complement
sera
patient
phase
iiphas
iii
induc
cell
hpec
lysi
sera
healthi
control
cytotox
index
cell
ae
vs
ae
p
hpec
ae
vs
ae
p
fig
b
huvec
cytotox
index
patient
healthi
control
differ
significantli
ae
vs
ae
p
fig
sar
new
emerg
infecti
diseas
global
impact
diagnosi
confirm
posit
viral
pcr
patient
also
found
elev
igg
igm
antibodi
sarscov
nucleocapsid
protein
later
phase
although
pathogen
identifi
underli
pathogenesi
yet
determin
prospect
studi
peiri
et
al
conclud
clinic
progress
sar
triphas
pattern
accord
clinic
present
patholog
chang
phase
first
week
character
fever
myalgia
system
symptom
suppos
effect
viral
rapid
replic
cytolysi
diseas
progress
phase
ii
phase
iii
rate
viral
shed
nasopharynx
stool
urin
decreas
gradual
howev
sever
clinic
worsen
often
occur
time
peiri
et
al
poon
et
al
addit
pulmonari
damag
autopsi
also
reveal
system
vascul
ding
et
al
lang
et
al
taken
togeth
therapeut
effect
immunoglobulin
steroid
block
diseas
progress
ho
et
al
find
suggest
later
phase
sar
relat
immunopatholog
damag
focus
immunemedi
pathogenesi
sarscov
infect
found
studi
autoantibodi
develop
around
month
onset
diseas
includ
igg
cell
antibodi
igm
antihpec
antibodi
igg
antihuvec
antibodi
mani
wellestablish
method
detect
antibodi
whole
cell
use
fluoresceinconjug
antisera
human
immunoglobulin
indirect
immunofluoresc
stain
standard
method
high
specif
howev
method
limit
low
sensit
lindquist
osterland
tan
pearson
praprotnik
et
al
cellbas
elisa
method
use
wide
assay
whole
cell
differ
sourc
use
substrat
fix
glutaraldehyd
treatment
procedur
cell
fixat
may
lead
falseposit
result
probabl
autoantibodi
react
intracellular
antigen
also
detect
well
therefor
specif
method
limit
meroni
et
al
praprotnik
et
al
test
describ
advantag
limit
order
confirm
result
studi
use
two
method
obtain
confirm
laboratori
data
previou
studi
aepca
limit
certain
epitheli
cell
differ
tissu
mucos
epitheli
cell
pemphigu
recurr
oral
ulcer
intestin
epitheli
cell
ulcer
coliti
snook
et
al
sun
et
al
colon
et
al
literatur
concern
aepca
detect
disord
pulmonari
involv
use
respiratori
tract
epitheli
cell
target
cell
cell
easili
avail
commonli
use
human
respiratori
epitheli
celllin
use
substrat
studi
result
show
develop
igg
cell
antibodi
sar
patient
patient
streptococc
necrot
pneumonia
first
report
associ
autoantibodi
develop
infecti
pulmonari
disord
contrast
aepca
aeca
extens
studi
aeca
found
wide
rang
diseas
especi
system
autoimmun
diseas
primari
autoimmun
vascul
carvalho
et
al
toyoda
et
al
praprotnik
et
al
grunebaum
et
al
yang
et
al
lee
et
al
lin
et
al
vasculopathi
vascul
may
develop
viral
infect
includ
hepat
c
viru
hcv
cacoub
et
al
cytomegaloviru
cmv
toyoda
et
al
dengu
viru
lin
et
al
condit
aeca
could
also
detect
sar
primarili
affect
lung
vasculopathi
vascul
organ
also
found
diseas
progress
ding
et
al
lang
et
al
phenomenon
indic
sarscov
like
hcv
cmv
dengu
viru
may
abil
damag
vessel
directli
indirectli
may
reason
igm
antihpec
antibodi
igg
antihuvec
antibodi
could
detect
sar
patient
anoth
relev
find
studi
reveal
iga
antihpec
iga
antihuvec
antibodi
although
statist
increas
phase
decreas
significantli
diseas
progress
phase
ii
phase
iii
phenomenon
may
explain
invas
sarscov
activ
mucosaassoci
immun
system
special
system
iga
globulin
fig
immunofluoresc
analysi
bind
activ
igg
antibodi
cell
b
igm
antibodi
hpec
c
igg
antibodi
huvec
patient
streptococc
necrot
pneumonia
row
healthi
control
row
sar
patient
phase
iiphas
iii
row
pb
use
test
control
elimin
nonspecif
bind
row
product
induc
format
iga
aeca
declin
gradual
viral
load
decreas
mechan
autoantibodi
develop
sar
patient
specul
contact
sarscov
possibl
epitheli
cell
surfac
receptor
recent
identifi
angiotensinconvert
enzym
viru
invad
epitheli
cell
directli
observ
electro
microscop
peiri
et
al
first
week
phase
sarscov
replic
rapidli
induc
cytolysi
time
macrophag
accumul
around
local
inflammatori
site
activ
macrophag
cell
may
releas
tumor
necrosi
factora
proinflammatori
cytokin
increas
sarscov
infect
beij
group
nation
research
project
sar
ng
et
al
damag
cell
stimul
proinflammatori
cytokin
may
reveal
cryptic
autoantigen
macrophag
infiltr
around
lesion
may
play
anoth
role
antigen
present
cell
initi
process
adapt
immun
lead
format
autoantibodi
howev
patient
necrot
pneumonia
character
sever
pulmonari
cell
damag
increas
proinflammatori
cytokin
phenomenon
anoth
possibl
may
sarscov
share
specif
antigen
determin
epitheli
cell
endotheli
cell
individu
antibodi
primarili
viru
crossreact
cell
due
molecular
mimicri
autoantibodi
cell
like
aeca
function
heterogen
probabl
depend
specif
bordron
et
al
may
epiphenomenon
pulmonari
epitheli
vascular
injuri
could
also
pathogen
role
caus
cellular
damag
apoptosi
complement
antibodydepend
cytotox
pathway
bordron
et
al
lin
et
al
worda
et
al
sar
patient
found
autoantibodi
bind
epitheli
cell
endotheli
cell
could
activ
complement
system
induc
cell
lysi
summari
although
studi
design
perform
identifi
diseasespecif
autoantigen
presenc
aepca
aeca
sarscov
infect
may
repres
sever
pulmonari
injuri
vascular
damag
sar
patient
autoantibodi
also
seem
potenti
damag
epitheli
cell
endotheli
cell
reaction
provid
anoth
immunolog
clue
better
understand
pathogenesi
sar
possibl
pathogen
potenti
autoantibodi
suggest
exclud
possibl
crossreact
primari
cell
develop
sar
vaccin
fig
complementdepend
cytotox
assay
sera
sar
patient
n
phase
iiphas
iii
autoantibodi
healthi
control
n
use
cell
b
hpec
c
huvec
lowtoxm
rabbit
complement
dilut
incub
preinactiv
sera
cytotox
effect
evalu
supernat
level
lactat
dehydrogenas
data
calcul
express
cytotox
index
p
p
